Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: A systematic review and meta-analysis

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 167, Issue 1, 2013, Pages 81-85

  Lin, Jiaying ^a   Qin, Jinbao ^b   Sangvatanakul, Voramon ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

CA125; Human epididymis protein 4; Meta analysis; Ovarian neoplasms; Risk of ovarian malignancy algorithm

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4;

AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; GYNECOLOGIC DISEASE; HUMAN; IMMUNOASSAY; META ANALYSIS; OVARY CANCER; OVARY CARCINOMA; OVARY TUMOR; PREDICTION; PRIORITY JOURNAL; RISK OF OVARIAN MALIGNANCY ALGORITHM; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

EID: 84874525890     PISSN: 03012115     EISSN: 18727654     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2012.10.036     Document Type: Article

References (32)

1. N. Einhorn, B. Nilsson, and K. Sjovall Factors influencing survival in carcinoma of the ovary. Study from a well-defined Swedish population Cancer 55 1985 2019 2025
2. M.E. Carney, J.M. Lancaster, C. Ford, A. Tsodikov, and C.L. Wiggins A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? Gynecologic Oncology 84 2002 36 42
3. T. Maggino, A. Gadducci, and V. D'Addario Prospective multicenter study on CA 125 in postmenopausal pelvic masses Gynecologic Oncology 54 1994 117 123
4. L.D. Roman, L.I. Muderspach, S.M. Stein, S. Laifer-Narin, S. Groshen, and C.P. Morrow Pelvic examination, tumor marker level, and gray-scale and Doppler sonography in the prediction of pelvic cancer Obstetrics and Gynecology 89 1997 493 500
5. J.M. McDonald, S. Doran, and C.P. DeSimone Predicting risk of malignancy in adnexal masses Obstetrics and Gynecology 115 4 2010 687 694
6. P. Buamah Benign conditions associated with raised serum CA-125 concentration Journal of Surgical Oncology 75 2000 264 265
7. I. Jacobs, and R.C. Bast Jr. The CA 125 tumour-associated antigen: a review of the literature Human Reproduction 4 1989 1 12
8. R.G. Moore, A.K. Brown, and M.C. Miller The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass Gynecologic Oncology 108 2008 402 408
9. R. Drapkin, H.H. von Horsten, and Y. Lin Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas Cancer Research 65 2005 2162 2169
10. P. Whiting, A.W. Rutjes, J.B. Reitsma, P.M. Bossuyt, and J. Kleijnen The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews BMC Medical Research Methodology 3 2003 25
11. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Controlled Clinical Trials 7 1986 177 188
12. 2 index? Psychological Methods 11 2006 193 206
13. J. Dinnes, J. Deeks, J. Kirby, and P. Roderick A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy Health Technology Assessment 9 2005 1 113 iii.
14. M.R. Andersen, B.A. Goff, and K.A. Lowe Use of a symptom index, CA125, and HE4 to predict ovarian cancer Gynecologic Oncology 116 2010 378 383
15. L.J. Havrilesky, C.M. Whitehead, and J.M. Rubatt Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence Gynecologic Oncology 110 2008 374 382
16. R.G. Moore, D.S. McMeekin, and A.K. Brown A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass Gynecologic Oncology 112 2009 40 46
17. Y. Park, J.H. Lee, D.J. Hong, E.Y. Lee, and H.S. Kim Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases Clinical Biochemistry 44 2011 884 888
18. Z. Yurkovetsky, S. Skates, and A. Lomakin Development of a multimarker assay for early detection of ovarian cancer Journal of Clinical Oncology 28 2010 2159 2166
19. I. Hellstrom, J. Raycraft, and M. Hayden-Ledbetter The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma Cancer Research 63 2003 3695 3700
20. M. Montagnana, G. Lippi, and O. Ruzzenente The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass Journal of Clinical Laboratory Analysis 23 2009 331 335
21. T. Van Gorp, I. Cadron, and E. Despierre HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm British Journal of Cancer 104 2011 863 870
22. R. Molina, J.M. Escudero, and J.M. Auge HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases Tumour Biology 32 2011 1087 1095
23. K. Partheen, B. Kristjansdottir, and K. Sundfeldt Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass Journal of Gynecologic Oncology 22 2011 244 252
24. K. Huhtinen, P. Suvitie, and J. Hiissa Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts British Journal of Cancer 100 2009 1315 1319
25. B. Nolen, L. Velikokhatnaya, and A. Marrangoni Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass Gynecologic Oncology 117 2010 440 445
26. H.A. Abdel-Azeez, H.A. Labib, S.M. Sharaf, and A.N. Refai HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses Asian Pacific Journal of Cancer Prevention 11 2010 111 116
27. F. Jacob, M. Meier, and R. Caduff No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting Gynecologic Oncology 121 2011 487 491
28. X. Chang, X. Ye, and L. Dong Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma International Journal of Gynecological Cancer 21 2011 852 858
29. Y. Park, Y. Kim, E.Y. Lee, J.H. Lee, and H.S. Kim Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer International Journal of Cancer 130 2012 1136 1144
30. K. Holcomb, Z. Vucetic, M.C. Miller, and R.C. Knapp Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women American Journal of Obstetrics and Gynecology 205 2011 358e1 358e6
31. L.R. Medeiros, D.D. Rosa, M.I. da Rosa, and M.C. Bozzetti Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review European Journal of Obstetrics, Gynecology, and Reproductive Biology 142 2009 99 105
32. R.G. Moore, M. Jabre-Raughley, and A.K. Brown Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass American Journal of Obstetrics and Gynecology 203 2010 228e1 228e6